Exhibit 99.1

MDxHealth SA and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Three Months Ended March 31,
In thousands of $ (except per share amounts)	2024			2023
Revenues	$	19,834		$	14,700
Cost of sales (exclusive of amortization of intangible assets)		(7,771	)		(5,985	)
Gross profit		12,063			8,715
Research and development expenses		(2,164	)		(1,316	)
Selling and marketing expenses		(10,028	)		(9,099	)
General and administrative expenses		(5,359	)		(5,169	)
Amortization of intangible assets		(1,125	)		(1,124	)
Other operating income (expense), net		9			(724	)
Operating loss		(6,604	)		(8,717	)
Financial expenses, net		(1,907	)		(2,992	)
Loss before income tax		(8,511	)		(11,709	)
Income tax		–			–
Loss for the period	$	(8,511	)	$	(11,709	)
Loss per share attributable to parent*
Basic and diluted	$	(0.31	)	$	(0.53	)

* The company completed a share consolidation with respect to all its outstanding shares by means of a 1-for-10 reverse stock split as of November 13, 2023. All share amounts and the EPS were adjusted retroactively to reflect the reverse stock-split.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Thousands of $	March 31, 2024			December 31, 2023
ASSETS
Non-current assets
Goodwill	$	35,926		$	35,926
Intangible assets		43,757			44,337
Property, plant and equipment		4,758			4,956
Right-of-use assets		4,625			4,989
Financial assets		693			763
Total non-current assets		89,759			90,971
Current assets
Inventories		3,044			2,779
Trade receivables		12,669			11,088
Prepaid expenses and other current assets		1,779			1,914
Cash and cash equivalents		14,494			22,380
Total current assets		31,986			38,161
TOTAL ASSETS	$	121,745		$	129,132
EQUITY
Share capital	$	173,931		$	173,931
Issuance premium		153,177			153,177
Accumulated deficit		(339,957	)		(331,446	)
Share-based compensation		12,307			12,139
Translation reserve		(431	)		(593	)
Total equity		(973	)		7,208
LIABILITIES
Non-current liabilities
Loans and borrowings		35,775			35,564
Lease liabilities		3,115			3,578
Other non-current financial liabilities		64,878			63,259
Total non-current liabilities		103,768			102,401
Current liabilities
Loans and borrowings		645			643
Lease liabilities		1,564			1,480
Trade payables		8,759			8,811
Other current liabilities		6,258			5,694
Other current financial liabilities		1,724			2,895
Total current liabilities		18,950			19,523
Total liabilities		122,718			121,924
TOTAL EQUITY AND LIABILITIES	$	121,745		$	129,132

2

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Three Months Ended March 31,
Thousands of $ For the years ended December 31	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES
Operating loss	$	(6,604	)	$	(8,717	)
Depreciation		775			512
Amortization of intangible assets		1,125			1,124
Share-based compensation		168			158
Other non-cash transactions		(1	)		815
Cash used in operations before working capital changes		(4,537	)		(6,108	)
Increase (-) / decrease (+) in inventories		(265	)		297
Increase (-) / decrease (+) in receivables		(1,392	)		346
Increase (+) in payables		679			1,197
Net cash outflow from operating activities		(5,515	)		(4,268	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(220	)		(787	)
Acquisition and generation of intangible assets		(544	)		(455	)
Interests received		146			4
Net cash outflow from investing activities		(618	)		(1,238	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of shares, net of transaction costs		-			39,599
Repayment of loan obligation		(160	)		(158	)
Payment of lease liability		(475	)		(348	)
Payment of interest		(947	)		(831	)
Other financial expenses		(170	)		-
Net cash (outflow) inflow from financing activities		(1,752	)		38,262
Net decrease (-) / increase (+) in cash and cash equivalents		(7,885	)		32,756
Cash and cash equivalents at beginning of period		22,380			15,503
Effect on exchange rate changes		(1	)		(5	)
Cash and cash equivalents at end of period	$	14,494		$	48,254

3